Bio-Techne Corporation logo
TECHBio-Techne Corporation

Is the current ratio high or low?

The current ratio of 4.49 is 10% above its 5-year average of 4.07, near the high end of its 5-year range (3.35–4.84).

As of Sunday, June 28, 2026. 9.96% above its 12-month average of 4.08.

Quick Ratio|Debt to Equity|P/B Ratio|All Metrics
Current Ratio

TECH Current Ratio

4.49

Reported quarterly current ratio; no daily interpolation.

+33.88% 5Y
TECH Current Ratio

TECH Average Current Ratio Chart

TECH Current Ratio

TECH Current vs Average Current Ratio Chart

TECH Current Ratio Metrics

CURRENT RATIO

4.49

CURRENT RATIO AVG TTM

4.08

CURRENT RATIO AVG 3Y

4.21

CURRENT RATIO AVG 5Y

4.07

CURRENT RATIO AVG 10Y

4.14

CURRENT RATIO AVG 15Y

4.70

CURRENT RATIO AVG 20Y

8.23

CURRENT VS TTM AVG

+9.96%

CURRENT VS 3Y AVG

+6.61%

CURRENT VS 5Y AVG

+10.27%

CURRENT VS 10Y AVG

+8.35%

CURRENT VS 15Y AVG

-4.54%

CURRENT VS 20Y AVG

-45.43%

TECH Competitors' Current Ratio

NAMEMARKET CAPCURRENT RATIOTTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B4.494.084.214.07
Insulet Corp. (PODD)vs ›$10.96B2.783.163.344.18
Baxter International Inc. (BAX)vs ›$11.38B2.311.831.711.91
Charles River Laboratories International, Inc. (CRL)vs ›$10.39B1.291.351.391.37
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B0.680.660.700.70
Molina Healthcare, Inc. (MOH)vs ›$11.97B1.691.661.581.56
Tempus AI, Inc. (TEM)vs ›$9.80B3.132.712.363.23
Henry Schein, Inc. (HSIC)vs ›$9.68B1.381.401.561.60
Revvity, Inc. (RVTY)vs ›$12.61B1.682.642.372.14
Align Technology, Inc. (ALGN)vs ›$12.78B1.361.291.261.29

Liquidity Analysis

Current Ratio

4.49

Quick Ratio

2.38

Current Ratio Formula & Definition

Current Ratio = Current Assets / Current Liabilities

The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Current Ratio FAQ

What is the current ratio for Bio-Techne Corporation (TECH)?
The current ratio for TECH stock is 4.49.
Is Bio-Techne Corporation's current ratio high or low?
The current ratio of 4.49 is 10% above its 5-year average of 4.07, near the high end of its 5-year range (3.35–4.84).
What is the TTM average current ratio for Bio-Techne Corporation (TECH)?
The TTM average current ratio for TECH stock is 4.08.
What is the 3Y average current ratio for Bio-Techne Corporation (TECH)?
The 3Y average current ratio for TECH stock is 4.21.
What is the 5Y average current ratio for Bio-Techne Corporation (TECH)?
The 5Y average current ratio for TECH stock is 4.07.
What is the 10Y average current ratio for Bio-Techne Corporation (TECH)?
The 10Y average current ratio for TECH stock is 4.14.
What is the 15Y average current ratio for Bio-Techne Corporation (TECH)?
The 15Y average current ratio for TECH stock is 4.70.
What is the 20Y average current ratio for Bio-Techne Corporation (TECH)?
The 20Y average current ratio for TECH stock is 8.23.

TECH Current Ratio History

DATECURRENT RATIO
2026-03-314.49
2025-12-314.54
2025-09-304.22
2025-06-303.46
2025-03-313.71
2024-12-313.94
2024-09-304.56
2024-06-303.87
2024-03-314.08
2023-12-314.37
2023-09-304.63
2023-06-304.84
2023-03-314.04
2022-12-314.40
2022-09-304.01
2022-06-303.44
2022-03-313.55
2021-12-313.81
2021-09-304.06
2021-06-303.35
2021-03-314.12
2020-12-314.61
2020-09-305.14
2020-06-304.88
2020-03-314.69
2019-12-314.43
2019-09-304.44
2019-06-304.05
2019-03-314.32
2018-12-314.35
2018-09-304.59
2018-06-305.06
2018-03-315.53
2017-12-313.10
2017-09-302.87
2017-06-302.55
2017-03-312.15
2016-12-312.44
2016-09-302.90
2016-06-304.69
2016-03-315.60
2015-12-317.21
2015-09-305.35
2015-06-306.24
2015-03-317.65
2014-12-316.18
2014-09-306.60
2014-06-3017.79
2014-03-3113.11
2013-12-3112.63
2013-09-3013.84
2013-06-3012.76
2013-03-3112.01
2012-12-3116.91
2012-09-3015.29
2012-06-309.69
2012-03-319.97
2011-12-3116.09
2011-09-308.35
2011-06-3012.67
2011-03-3116.73
2010-12-3118.55
2010-09-3014.52
2010-06-3011.81
2010-03-3111.11
2009-12-3121.99
2009-09-3017.57
2009-06-3016.46
2009-03-3114.93
2008-12-3114.81
2008-09-3012.95
2008-06-3012.77
2008-03-3112.86
2007-12-3111.98
2007-09-3015.62
2007-06-3012.38
2007-03-3112.25
2006-12-3113.75
2006-09-305.91
2006-06-308.34
2006-03-3110.79
2005-12-319.49
2005-09-3010.56
2005-06-309.63
2005-03-316.10
2004-12-3111.39
2004-09-309.07
2004-06-3015.67
2004-03-3113.94
2003-12-3114.47
2003-09-3015.49
2003-06-3013.83
2003-03-3110.17
2002-12-3111.44
2002-09-306.90
2002-06-308.82

Related Metrics

Quick RatioDebt to EquityP/B RatioAll Metrics

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
www.bio-techne.com
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman
View full financials